Pfizer PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. today announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI® (enzalutamide) in men with...
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 that available data...
Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The...
Pfizer (NYSE:PFE) faces a $16 to $18 billion loss in revenue from 2025 through 2030 as it loses essential patents on five drugs.The drugs account for 40% of the company's Q3...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Sell | Sell | Strong Sell | Sell | Buy |
Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Buy | Strong Buy |
Summary | Strong Sell | Strong Sell | Strong Sell | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
3.63 | 3.68 | 3.58 | +0.080 | +2.25% | 11.66M | Philippines | |||
14.34 | 14.34 | 14.34 | 0.00 | 0.00% | 132.90K | Philippines | |||
51.20 | 52.60 | 51.10 | -1.150 | -2.20% | 303.47K | Philippines | |||
14.14 | 14.28 | 13.96 | +0.400 | +2.91% | 2.39M | Philippines | |||
5.30 | 5.30 | 5.30 | 0.00 | 0.00% | 0.00 | Philippines | |||
13.68 | 13.90 | 13.60 | +0.12 | +0.88% | 1.91M | Philippines | |||
58.50 | 58.50 | 57.20 | +1.30 | +2.27% | 1.86M | Philippines | |||
1,850.00 | 1,875.00 | 1,846.00 | +2.00 | +0.11% | 67.08K | Philippines | |||
4.92 | 4.93 | 4.90 | 0.00 | 0.00% | 352.00K | Philippines | |||
9.99 | 10.08 | 9.99 | -0.010 | -0.10% | 1.05M | Philippines | |||
12.78 | 13.06 | 12.76 | -0.200 | -1.54% | 564.60K | Philippines | |||
34.00 | 34.05 | 33.65 | 0.00 | 0.00% | 8.64M | Philippines | |||
5.29 | 5.30 | 5.26 | -0.01 | -0.19% | 275.30K | Philippines | |||
225.20 | 226.60 | 223.00 | +2.20 | +0.99% | 528.46K | Philippines | |||
0.89 | 0.90 | 0.87 | 0.00 | 0.00% | 0.00 | Philippines |